Tegaserod

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Chronic Constipation

Conditions

Chronic Constipation

Trial Timeline

Jul 1, 2006 → Apr 1, 2007

NCT ID

NCT00348634

About Tegaserod

Tegaserod is a approved stage product being developed by Novartis for Chronic Constipation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00348634. Target conditions include Chronic Constipation.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Constipation were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00511771	Pre-clinical	Completed	—	—	Irritable Bowel Syndrome With Constipation
NCT00414024	Phase 3	Terminated	Feb 1, 2007	May 1, 2007	Opioid-induced Constipation
NCT00390975	Approved	Terminated	Jan 1, 2007	Mar 1, 2007	Gastroparesis
NCT00399659	Phase 3	Terminated	Nov 1, 2006	Apr 1, 2007	Opioid-induced Constipation
NCT00365820	Phase 2/3	Terminated	Jul 1, 2006	Apr 1, 2007	Constipation
NCT00348634	Approved	Terminated	Jul 1, 2006	Apr 1, 2007	Chronic Constipation
NCT00171457	Phase 3	Completed	Apr 1, 2005	Sep 1, 2006	Heartburn
NCT00171470	Phase 3	Completed	Apr 1, 2005	Aug 1, 2006	Dyspepsia
NCT00139568	Phase 3	Completed	Feb 1, 2005	Oct 1, 2005	Constipation
NCT00563758	Pre-clinical	Terminated	Dec 1, 2004	Feb 1, 2006	Constipation
NCT00563615	Pre-clinical	UNKNOWN	Nov 1, 2004	Oct 1, 2006	Constipation
NCT00171431	Phase 3	Terminated	Nov 1, 2004	May 1, 2006	Constipation Predominant
NCT00232037	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232102	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232089	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Dyspepsia
NCT00142974	Phase 2	Terminated	May 1, 2004	Apr 1, 2005	Diabetic Gastropathy
NCT00142987	Approved	Completed	Apr 1, 2004	Jun 1, 2005	IBS-C and IBS With Mixed Bowel Habits
NCT00149877	Approved	Completed	Apr 1, 2004	Feb 1, 2006	Chronic Constipation
NCT00141089	Phase 3	Completed	Mar 1, 2004	Feb 1, 2005	Chronic Constipation
NCT00171483	Phase 3	Completed	Jan 1, 2004	Apr 1, 2005	Gastroesophageal Reflux Disease (GERD)

Competing Products

20 competing products in Chronic Constipation

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25